Juvlin 75 Capsule

About Juvlin 75 Capsule

Juvlin 75 is a capsule containing pregabalin 75 mg, an adjunct anti-epileptic medicine also used for certain types of nerve pain. It is made by MST Pharma and Healthcare Ltd.

There are 105 brands of Pregabalin listed in Bangladesh. The lowest listed price is GAPA-P 150 mg Capsule at ৳ 1 per unit.

What is Juvlin 75 Capsule?

Juvlin 75 is a capsule with the active ingredient pregabalin 75 mg. Pregabalin belongs to a group of medicines called adjunct anti-epileptic drugs. It is used in adults for nerve pain linked to diabetes or shingles, and for fibromyalgia or spinal cord injury. It is also added to other medicines to treat partial-onset seizures in patients from one month of age. Pregabalin works in the central nervous system, though its exact way of acting is not fully understood. Juvlin 75 is available only with a doctor's prescription.

Uses of Juvlin 75

Juvlin 75 is used for neuropathic pain from diabetic peripheral neuropathy or postherpetic neuralgia, for fibromyalgia, and for nerve pain after spinal cord injury. It is also used as adjunctive therapy for partial-onset seizures in patients one month and older. The doctor decides if it is suitable for you.

How to use Juvlin 75

Take Juvlin 75 exactly as your doctor tells you. Swallow the capsule whole with water; do not chew or open it. The dose and course are set by your doctor based on your condition, kidney function and response. Do not change the dose yourself. If you miss a dose, ask your doctor or pharmacist what to do. Do not stop the medicine suddenly without medical advice.

Side effects of Juvlin 75

Common side effects of pregabalin in adults include dizziness, sleepiness, dry mouth, swelling, blurred vision, weight gain and difficulty concentrating. In children treated for partial seizures, increased weight and increased appetite are common. Tell your doctor if side effects bother you. Seek urgent help for swelling of the face or throat, trouble breathing, or severe skin reactions.

Safety and precautions

Tell your doctor before using Juvlin 75 if you have kidney problems, breathing problems, or have ever had swelling of the face or throat, or allergic reactions. Pregabalin may increase suicidal thoughts or behaviour, so watch for mood changes. It can cause respiratory depression, especially with other CNS depressants. There are no adequate studies in pregnant women; the doctor will weigh the risks. Small amounts pass into breast milk, and breastfeeding is not recommended during treatment. Ask your doctor first if you are pregnant, planning pregnancy or breastfeeding.

Frequently asked questions

What is Juvlin 75 used for and what kind of medicine is it?

Juvlin 75 is an adjunct anti-epileptic medicine containing pregabalin. It is used for certain nerve pains, fibromyalgia, spinal cord injury pain, and as add-on treatment for partial-onset seizures. Your doctor will decide if it is right for you.

Which medicines may interact with Juvlin 75?

Pregabalin is unlikely to cause significant pharmacokinetic drug interactions. However, taking it with other central nervous system depressants may increase the risk of respiratory depression. Always tell your doctor or pharmacist about all medicines you take, including over-the-counter products.

Is Juvlin 75 safe in pregnancy or breastfeeding?

There are no adequate studies of pregabalin in pregnant women, so the doctor will assess the potential risk. Small amounts pass into breast milk, and breastfeeding is not recommended during treatment because of a potential risk of tumorigenicity. Ask your doctor before use.

Can I stop taking Juvlin 75 suddenly?

No, do not stop Juvlin 75 suddenly. Your doctor will decide how to reduce or stop it safely. Stopping suddenly may cause problems. Always follow your doctor's instructions about the dose and course.

Indications

Pregabalin is indicated for:
  • Neuropathic pain associated with diabetic peripheral neuropathy (DPN)
  • Postherpetic neuralgia (PHN)
  • Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older
  • Fibromyalgia
  • Neuropathic pain associated with spinal cord injury
  • ... Read more
Pregabalin is indicated for:
  • Neuropathic pain associated with diabetic peripheral neuropathy (DPN)
  • Postherpetic neuralgia (PHN)
  • Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older
  • Fibromyalgia
  • Neuropathic pain associated with spinal cord injury
Pregabalin CR tablet is indicated for:
  • Neuropathic pain associated with diabetic peripheral neuropathy (DPN)
  • Postherpetic neuralgia (PHN)

Pharmacology

Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It does not bind directly to GABAA, GABAB or benzodiazepine receptors. Pregabalin binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of Pregabalin has not been fully elucidated, results in animal studies suggest that binding to the alpha2-delta subunit may be involved in Pregabalin's anti-nociceptive and antiseizure effects.

Dosage & Administration

Neuropathic pain associated with diabetic peripheral neuropathy in adults (DPN): The maximum recommended dose of Pregabalin is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 ml/min. Dosing should begin at 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Begin dosing of Pregabalin CR capsule at 165 mg once daily and increase to 330 mg once daily within 1 week based on individual patient response and tolerability. The maximum recommended dose of Pregabalin CR capsule is 330 mg once daily.

Postherpetic neuralgia in adults (PHN): The recommended dose of Pregabalin is 75 to 150 mg two times a day or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 ml/min. Dosing should begin at 75 mg two times a day or 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 300 mg/day and who are able to tolerate Pregabalin, may be treated with up to 300 mg two times a day or 200 mg three times a day (600 mg/day).

Begin dosing of Pregabalin CR capsule at 165 mg once daily and increase to 330 mg once daily within 1 week based on individual patient response and tolerability. Patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 330 mg once daily and who are able to tolerate Pregabalin CR capsule, may be treated with up to 660 mg once daily. In view of the dose-dependent adverse reactions and the higher rate of treatment discontinuation due to adverse reactions, dosing above 330 mg/day should be reserved only for those patients who have on-going pain and are tolerating 330 mg daily. The maximum recommended dose of Pregabalin CR capsule is 660 mg once daily.

Management of fibromyalgia in adults: The recommended dose of Pregabalin is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day).

Neuropathic pain associated with spinal cord injury in adults: The recommended dose range of Pregabalin is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient pain relief after 2 to 3 weeks of treatment with 150 mg two times a day and who tolerate Pregabalin may be treated with up to 300 mg two times a day.

Conversion from Pregabalin capsules to Pregabalin CR capsule tablet: When switching from Pregabalin capsules to Pregabalin CR capsule tablet on the day of the switch, instruct patients to take their morning dose of Pregabalin capsule as prescribed and initiate Pregabalin CR capsule therapy after an evening meal.

Pregabalin tablet total daily dose (dosed 2 or 3 times daily): Pregabalin CR capsule capsule dose (dosed once a day)
  • 75 mg/daily: 82.5 mg/day
  • 150 mg/daily: 165 mg/day
  • 225 mg/daily: 247.5 mg/day
  • 300 mg/daily: 330 mg/day
  • 450 mg/daily: 495 mg/day
  • 600 mg/daily: 660 mg/day

Interaction

Pregabalin is unlikely to be involved in significant pharmacokinetic drug interactions.

Contraindications

Pregabalin is contraindicated in patients with known hypersensitivity to Pregabalin or any of its components.

Side Effects

Most common side effects in adults are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain and thinking abnormal (primarily difficulty with concentration/attention). Most common side effects in pediatric patients for the treatment of partial onset seizures are increased weight and increased appetite.

Pregnancy & Lactation

There are no adequate and well-controlled studies with pregabalin in pregnant women. Pregnant women should be advised of the potential risk to a fetus. Small amounts of pregabalin have been detected in the milk of lactating women. Because of the potential risk of tumorigenicity, breastfeeding is not recommended during treatment with pregabalin.

Precautions & Warnings

Angioedema (e.g., swelling of the throat, head and neck) can occur and may be associated with life threatening respiratory compromise requiring emergency treatment. Pregabalin should be discontinued immediately in these cases. Pregabalin should also be discontinued immediately if hypersensitivity reactions (e.g., hives, dyspnea and wheezing) occur. Antiepileptic drugs, including pregabalin, increase the risk of suicidal thoughts or behavior. Respiratory depression may occur with pregabalin when used with concomitant CNS depressants or in the setting of underlying respiratory impairment. Patients need to be monitored and dosage adjusted as appropriate. Pregabalin may cause dizziness and somnolence and impair patients ability to drive or operate machinery. Increased seizure frequency or other adverse reactions may occur if pregabalin is rapidly discontinued. Pregabalin should be withdrawn gradually over a minimum of 1 week. Pregabalin may cause peripheral edema. Caution should be exercised when coadministering pregabalin and thiazolidinedione antidiabetic agents.

Overdose Effects

In case of overdose with pregabalin, sign and symptoms are reduced consciousness, depression/anxiety, confusional state, agitation and restlessness. Seizures and heart block have also been reported. There is no specific antidote. If indicated, elimination of unabsorbed drug may be attempted by emesis or gastric lavage; usual precautions should be observed to maintain the airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the clinical status of the patient.

Storage Conditions

Keep in a cool & dry place (below 30°C), protected from light & moisture. Keep out of the reach of children.

Alternative brands of Pregabalin

Other brands with the same generic name, cheapest first.

Gabarol Capsule

25 mg

Pregabalin

Advanced Chemical Industries PLC

৳ 11.00 per unit

Algaba Capsule

50 mg

Pregabalin

Al-Madina Pharmaceuticals Ltd.

৳ 12.00 per unit

See all 105 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.